Vasuda Global Orphan/Rare Disease Index Announces The Quarterly Recomposition And Rebalancing
Seven new index components were added while one was removed
(updated 62 index components)
Andover, Massachusetts: Vasuda Indices, LLC and Vasuda Capital Management announced the quarterly changes to the Vasuda Global Orphan/Rare Disease Index, the only global equity index tracking the orphan/rare disease index.
“With the addition of seven new index components and removal of one index components, the updated number of index components is 62.”, said Bhavneesh Sharma, MD, MBA, Managing Principal of Vasuda Indices, LLC and Vasuda Capital Management.
The newly included index components are all NASDAQ listed companies: Avexis (AVXS), Ra Pharmaceuticals (RARX), Crispr Therapeutics (CRSP), ProQr Therapeutics (PRQR), Abeona Therapeutics (ABEO), Corbus Pharmaceuticals (CRBP), and Catalyst Pharmaceuticals (CPRX).
The index has outperformed the benchmark, Nasdaq Biotechnology Index on backtest since 2010. The index live inception date is November 25, 2015. The index factsheet, list of components and live charts can be accessed at www.vasudaindices.com. The index is available for licensing to create an exchangetraded product.
About Vasuda Capital Management: Vasuda Capital Management is a Greater Boston based investment advisory and asset management firm. 'Vasuda' is a Sanskrit word meaning 'granting wealth.'
The firm is licensed as Registered Investment Adviser in Massachusetts. The firm offers separate managed investment accounts for individual and institutional investors (investing in publicly traded healthcare (primarily emerging pharmaceutical and biotechnology) companies. Interactive Brokers, LLC is the custodian and clearing agent for client assets. The firm also sponsors Vasuda Global Orphan/ Rare Diseases Biotechnology Index, the first of its kind (in partnership with Solactive A.G.). The index is available for licensing for an exchange-traded product.
Andover, Massachusetts: Vasuda Indices, LLC and Vasuda Capital Management announced the quarterly changes to the Vasuda Global Orphan/Rare Disease Index, the only global equity index tracking the orphan/rare disease index.
“With the addition of seven new index components and removal of one index components, the updated number of index components is 62.”, said Bhavneesh Sharma, MD, MBA, Managing Principal of Vasuda Indices, LLC and Vasuda Capital Management.
The newly included index components are all NASDAQ listed companies: Avexis (AVXS), Ra Pharmaceuticals (RARX), Crispr Therapeutics (CRSP), ProQr Therapeutics (PRQR), Abeona Therapeutics (ABEO), Corbus Pharmaceuticals (CRBP), and Catalyst Pharmaceuticals (CPRX).
The index has outperformed the benchmark, Nasdaq Biotechnology Index on backtest since 2010. The index live inception date is November 25, 2015. The index factsheet, list of components and live charts can be accessed at www.vasudaindices.com. The index is available for licensing to create an exchangetraded product.
About Vasuda Capital Management: Vasuda Capital Management is a Greater Boston based investment advisory and asset management firm. 'Vasuda' is a Sanskrit word meaning 'granting wealth.'
The firm is licensed as Registered Investment Adviser in Massachusetts. The firm offers separate managed investment accounts for individual and institutional investors (investing in publicly traded healthcare (primarily emerging pharmaceutical and biotechnology) companies. Interactive Brokers, LLC is the custodian and clearing agent for client assets. The firm also sponsors Vasuda Global Orphan/ Rare Diseases Biotechnology Index, the first of its kind (in partnership with Solactive A.G.). The index is available for licensing for an exchange-traded product.